Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess it take awhile to read the news. Can you say undervalued!
This is great but I don't they even need an FDA approval for China. Remember NVDL? Correct me if I am wrong!
Go FCSC==================================>
HOD 1.12!
HOD 1.12!
Looking nice!
HOD 1.07
LEt's Do It!
5k sell
some buys during the meeting
Meeting in 2 mins!
Kind of funny how everyone was waiting for the PR yesterday and they questioned if JIM would come thru....AND BAM NEWS FLASH
can't wait til the end of the month!
Jim is a man of his word!
What time is the meeting?
Forgot to give you credit....nice find PennyFinch!
wish i had 100,000 shares!
I guess it takes time to read the news..........
TIC TIC TIC TIC TIC TIC
TIC TIC TIC TIC TIC TIC...................
nice 20k buy!
I agree!
It's gonna run.....
Load the boat NOW!!!!!!!!!!
IntelGenx Announces Licensing of Anti-Psychotic VersaFilm Product
Intelgenx Technologs (OTCBB:IGXT)
Intraday Stock Chart
Today : Tuesday 14 June 2011
IntelGenx Corp. (TSX VENTURE: IGX)(OTCBB: IGXT) ("IntelGenx", or "the Company"), announced that it has executed a binding term-sheet with RedHill Biopharma Ltd. ("RedHill"), an Israeli corporation listed on the Tel Aviv Stock Exchange ("TASE") under the symbol RDHL, to co-develop and license an anti-psychotic oral thin film product based upon the Company's proprietary VersaFilm technology.
The term-sheet sets forth the main criteria to be incorporated into a definitive development and license agreement, subject to due diligence, under which RedHill would obtain exclusive worldwide rights to market and sell IntelGenx' rapidly dissolving anti-psychotic oral film product. In exchange, IntelGenx would receive upfront, milestone, and external development fees totalling up to US$2.3 million from RedHill. Furthermore, upon commercialization of the product, IntelGenx would receive up to 50% of all proceeds including, but not limited to, all sales milestones and income from the product world-wide. IntelGenx and RedHill have entered into a ninety-day exclusivity period, during which IntelGenx is prohibited from engaging in negotiations related to the product with any other party. The term-sheet also provides for a break-up fee in the event that IntelGenx or RedHill is unable to execute the licensing agreement, under certain circumstances, after the satisfactory completion of due diligence.
"We are excited to have entered into another partnership with RedHill for a VersaFilm product," said Dr. Horst G. Zerbe, President and Chief Executive Officer of IntelGenx. "VersaFilm is at the forefront of new technology aimed at delivering medicine in a manner that could offer some unique advantages over conventional oral delivery, especially in patients with anti-psychotic behavioural symptoms where patient compliance is an issue."
In February 2011, IntelGenx announced the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-psychotic therapy. The product has been developed using IntelGenx' proprietary immediate release VersaFilm drug delivery technology, which provides a patent-protected method of formulating products in a more convenient and discrete dosage formulation.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of pain, hypertension, erectile dysfunction, sleep disorders, allergies and depressive disorders. More information is available about the company at www.intelgenx.com.
About RedHill Biopharma:
RedHill Biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. RedHill has an experienced management team, Board of Directors and Advisory Board based in Israel, the US, Canada and Europe, with a successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2010, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Each of the TSX Venture Exchange and OTC Bulletin Board has neither approved nor disapproved the contents of this press release.
Contacts:
IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
+1 514-331-7440 (ext. 201)
+1 514-331-0436 (FAX)
horst@intelgenx.com
www.intelgenx.com
don't know if yall saw this on IGXT:
IntelGenx Announces Licensing of Anti-Psychotic VersaFilm Product
Intelgenx Technologs (OTCBB:IGXT)
Intraday Stock Chart
Today : Tuesday 14 June 2011
IntelGenx Corp. (TSX VENTURE: IGX)(OTCBB: IGXT) ("IntelGenx", or "the Company"), announced that it has executed a binding term-sheet with RedHill Biopharma Ltd. ("RedHill"), an Israeli corporation listed on the Tel Aviv Stock Exchange ("TASE") under the symbol RDHL, to co-develop and license an anti-psychotic oral thin film product based upon the Company's proprietary VersaFilm technology.
The term-sheet sets forth the main criteria to be incorporated into a definitive development and license agreement, subject to due diligence, under which RedHill would obtain exclusive worldwide rights to market and sell IntelGenx' rapidly dissolving anti-psychotic oral film product. In exchange, IntelGenx would receive upfront, milestone, and external development fees totalling up to US$2.3 million from RedHill. Furthermore, upon commercialization of the product, IntelGenx would receive up to 50% of all proceeds including, but not limited to, all sales milestones and income from the product world-wide. IntelGenx and RedHill have entered into a ninety-day exclusivity period, during which IntelGenx is prohibited from engaging in negotiations related to the product with any other party. The term-sheet also provides for a break-up fee in the event that IntelGenx or RedHill is unable to execute the licensing agreement, under certain circumstances, after the satisfactory completion of due diligence.
"We are excited to have entered into another partnership with RedHill for a VersaFilm product," said Dr. Horst G. Zerbe, President and Chief Executive Officer of IntelGenx. "VersaFilm is at the forefront of new technology aimed at delivering medicine in a manner that could offer some unique advantages over conventional oral delivery, especially in patients with anti-psychotic behavioural symptoms where patient compliance is an issue."
In February 2011, IntelGenx announced the results of a clinical pilot study that suggests IntelGenx has successfully developed a product that is bioequivalent to a leading branded anti-psychotic therapy. The product has been developed using IntelGenx' proprietary immediate release VersaFilm drug delivery technology, which provides a patent-protected method of formulating products in a more convenient and discrete dosage formulation.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of pain, hypertension, erectile dysfunction, sleep disorders, allergies and depressive disorders. More information is available about the company at www.intelgenx.com.
About RedHill Biopharma:
RedHill Biopharma is a biopharmaceutical company focused primarily on development of late clinical-stage new, improved and patented formulations of existing drugs. RedHill has an experienced management team, Board of Directors and Advisory Board based in Israel, the US, Canada and Europe, with a successful track record at big and small pharma of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2010, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Each of the TSX Venture Exchange and OTC Bulletin Board has neither approved nor disapproved the contents of this press release.
Contacts:
IntelGenx Corp.
Dr. Horst G. Zerbe
President and CEO
+1 514-331-7440 (ext. 201)
+1 514-331-0436 (FAX)
horst@intelgenx.com
www.intelgenx.com
yeah I saw it at .25 nate from IL posted it. GLTY!
FCSC @ 1.05 glad i got some 1s
yeah cupcake for every one!
BEER too!
yeah cupcake for every one!
BEER too!
Very nice!
why the selling?
Nice volume!
Happy Birthday Nateeeeeeee!
Hope you make a lot of $$$$$$$ today!
Happy Birthday Nateeeeeeee!
Hope you make a lot of $$$$$$$ today!
GTGP We are currently finishing up the financials which will bring us up to date for uplifting to OTCBB. They should be completed for the year end June 30, 2011 and will be filed for that period prior to the final date for filing of that annual report
Global Technologies Group, Inc. Shareholders Letter
Global Techs Group (PL) (USOTC:GTGP)
Intraday Stock Chart
Today : Monday 13 June 2011
Global Technologies Group, Inc. (PINKSHEETS: GTGP) Global today announces status of all areas of business of the company to date.
Potential Acquisition
Global has completed all the necessary due diligence of the target company and the only remaining issue to be dealt with is the purchase price. Due to the timing of several large contracts which were entered into in the last few months the purchase price has been adjusted after each new contract was agreed to and accepted by the company to be acquired. As Global is moving through this process of evaluating the value of each new Global is formulating a purchase agreement with its' Investment banker whereby a price will be determined based on the present value of the company to include any additional new contracts which happen prior to a closing.
The current results of the joint venture agreements:
M2/MBS
MSE is authoring a report to be presented by them to the-the Annual Waste Management (WM) Conference, presented by WM Symposia (WMS), is widely regarded as the premier international conference on the management of radioactive materials and related topics. WM2012 is the 38th year of the conference and is expected to attract over 2,000 nuclear specialists from over 35 countries, presenting more than 500 papers in over 90 technical sessions. WMS was founded to provide a forum for discussing and seeking cost-effective and environmentally responsible solutions for the safe management and disposition of radioactive waste and radioactive materials. This year the conference theme for WM2012 is: Improving the Future in Waste Management. Sponsoring organizations include the American Nuclear Society (ANS), the American Society of Mechanical Engineers (ASME) and the Organization for Economic Co-operation and Development/Nuclear Energy Agency (OECD/NEA). The conference is also organized with input from the US Department of Energy (DOE), the US Nuclear Regulatory Commission (NRC), the US Environmental Protection Agency (EPA); the US Department of Defense (DOD) and the International Atomic Energy Agency (IAEA).
This is the next step for both M2 and Global as it puts the new combined technology tested and validated by MSE in front of the major government agencies they work with along with their credentials in this field. Both M2 and Global have also been in contact with several companies that are current clients and contacts of M2 and Global and were interested in the combined new product and were waiting for the final results and validation of the combined technologies which were achieved.
With the successful testing of MBS in a power plant for the successful removal of mercury from flu gas, we have been asked to provide a design for treatment of mercury for a well known Cement plant along with design features to retrofit the plant to use the MBS process. For this project, we are tasking MSE for design and implementation. It should be noted that the EPA has mandated all cement plants must confirm to the new regulations requiring the reduction and omission of mercury from their flu gas. Currently that encompasses over 140 thousand plants in this country alone.
M2/MSE/Global
We are preparing the required documents for submission for this 100 million dollar project with our partners.
NAVAL FACILITIES ENGINEERING COMMAND ATLANTIC ENVIRONMENTAL REMEDIAL ACTION CONTRACT (MOD)
SOL: N62470-11-R-8004
DUE: 071211 Indefinite Delivery Indefinite Quantity (ID/IQ) type contract for one base year and four one-year option periods. The total maximum value for the contract is $100 million inclusive of the base year and all options. Work will be performed by the issuance of task orders. The work includes remedial actions at environmentally contaminated sites predominately located at Navy and Marine Corps Installations and other Government agencies.
CITE: https://www.fbo.gov/?s=opportunity&mode=form&tab=core&id=e89e5ac78d3c8c5e045250a80445a179&_cview=0
Posted: 06/03/11
SPONSOR: N62470 NAVFAC ATLANTIC Code AQ 6506 Hampton Blvd, Building A Norfolk, VA
PUBLICATION DATE: June 5, 2011
ISSUE: FBO-3480
E.m.h.i. and Solucorp
We are currently compiling all information, testing and background data for all uses of Emhi IFS technology as well as all uses of the MBS technology unrelated to the original license grant between Solucorp and Global.
We are currently in additional negotiations for sub licenses with several companies for use in various parts of the U.S. and the Middle East, for various technologies under license and joint Ventures.
We are also currently reviewing several brown field projects for remediation and redevelopment in several states which includes redevelopment agencies.
Middle East
In Israel, we are working with a well know law group both with offices in the U.S. and Israel regarding the new mandate from the Israeli government that states all hazardous sites in Israel must and will be cleaned up.
Global is currently updating its website which will contain further background on all of the above and moving to new offices and transisitioning during the next few weeks. The website will not be down during the updating as all changes and additions will be done on our mirror site and simply will be active when finished. The time frame for the website change will be Friday, June 17, 2011.
Financials
We are currently finishing up the financials which will bring us up to date for uplifting to OTCBB. They should be completed for the year end June 30, 2011 and will be filed for that period prior to the final date for filing of that annual report.
For additional information on MSE, MBS, M2 and EMHI please visit our website at WWW.GLBTECH.COM
Global Technologies Group, Inc. (GLOBAL) is a company that is in the business of acquiring exclusive licenses and distribution and reseller contracts on proven technologies in the environmental, green and war fighter industries. The criteria for the licensing or distribution agreements of the technologies are: they must be proven, validated and in use. The business plan of Global is to sublicense the technologies it acquires to companies in Countries covered under the original license grants and for its own use. For our exclusive distribution and reseller agreements, we partner with appropriate representatives in the covered countries for resale of turn key projects.
Contact
James Fallacaro
Email Contact
941-685-1616
WWW.GLBTECH.COM
More GTGP MessagesLatest Global Techs Group (PL), GTGP Messages
belgian11 are you crazy!!! did you see the news....
Big question is: When is HDOGTX geting in or is he in already?
All the DD is there for him...lol
I say this only because he play PSP$!
Thanks Plano !
Thanks Jim for keeping your word even thou you had 100 ihubbers calling you!
Jim kept his words about the news!
Today is Moday june 13....and news came out today!
Jim kept his words about the news!
Today is Moday june 13....and news came out today!